APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224)
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (35 Sites)
Showing the first 25 of 35 sites.
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
- Moffitt — Tampa, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of North Carolina — Chapel Hill, North Carolina
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
- University of Wisconsin — Madison, Wisconsin
- St Vincents Hospital Melbourne — Melbourne,
- Cross Cancer Institute — Edmonton,
- McGill University Health Center - Research Institute — Montreal,
- Princess Margaret Hospital — Toronto,
- Cancer Care Manitoba — Winnipeg,
- CHRU de Brest - Hôpital Morvan — Brest,
- Centre Leon Berard — Lyon,
- Centre d'Essais Precoces en Cancerologie de Marseille — Marseille,
- Hopital Bichat - Claude Bernard - AP-HP — Paris,
- Gustave Roussy — Villejuif,
- Orszagos Koranyi Pulmonologiai Intezet — Budapest,
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz — Tatabánya,
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola — Bologna,
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori — Meldola,
- IRCCS Ospedale San Raffaele — Milan,
- Istituto Europeo di Oncologia — Milan,
- Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera — Padova,
- Private Medical Institution Euromedservice — Saint Petersburg,
- National Cancer Centre Singapore — Singapore,
📞 Contact the Study Coordinator
Phone: (650) 209-4055
Email: clinops@apollomicsinc.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.